Patents by Inventor Xingfang Hong

Xingfang Hong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6852727
    Abstract: Benzimidazo[4,5-f]isoquinolinone derivatives are inhibitors of Janus protein tyrosine kinases (Jak), and as such are useful as immunosuppressants, and in the treatment of diseases including asthma, allergies, autoimmune diseases.
    Type: Grant
    Filed: July 26, 2002
    Date of Patent: February 8, 2005
    Assignee: Merck & Co., Inc.
    Inventors: Joung L. Goulet, Rose M. Cubbon, Richard T. Cummings, Xingfang Hong, Peter J. Sinclair, James E. Thompson
  • Patent number: 6809199
    Abstract: Compounds described by the chemical formula (I) or a pharmaceutically acceptable salt thereof: are inhibitors of p38 useful in the treatment of inflammatory diseases such as arthritis.
    Type: Grant
    Filed: December 17, 2001
    Date of Patent: October 26, 2004
    Assignee: Merck & Co., Inc.
    Inventors: James B. Doherty, John E. Stelmach, Meng-Hsin Chen, Luping Liu, Julianne A. Hunt, Rowena D. Ruzck, Joung L. Goulet, David D. Wisnoski, Swaminathan Ravi Natarajan, Kathleen M. Rupprecht, Jianming Bao, Shouwu Miao, Xingfang Hong, Peter J. Sinclair, Florida Kallashi
  • Publication number: 20040176601
    Abstract: Benzimidazo[4,5-f]isoquinolinone derivatives are inhibitors of Janus protein tyrosine kinases (Jak), and as such are useful as immunosuppressants, and in the treatment of diseases including asthma, allergies, autoimmune diseases.
    Type: Application
    Filed: January 30, 2004
    Publication date: September 9, 2004
    Inventors: Joung L. Goulet, Rose M Cubbon, Richard T Cummings, Xingfang Hong, Peter J Sinclair, James E Thompson
  • Publication number: 20030092712
    Abstract: Compounds described by the chemical formula (I) or a pharmaceutically acceptable salt thereof: 1
    Type: Application
    Filed: December 17, 2001
    Publication date: May 15, 2003
    Inventors: James B. Doherty, John E. Stelmach, Meng-Hsin Chen, Luping Liu, Julianne A. Hunt, Rowena D. Ruzck, Joung L. Goulet, David D. Wisnoski, Swaminathan Ravi Natarajan, Kathleen M. Rupprecht, Jianming Bao, Shouwu Miao, Xingfang Hong, Peter J. Sinclair, Florida Kallashi
  • Patent number: 6498165
    Abstract: Pyrimidine compounds (Formula I), or their pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual diastereomers, and pharmaceutical compositions including the same, which are inhibitors of tyrosine kinase enzymes, and as such are useful in the prophylaxis and treatment of protein tyrosine kinase-associated disorders, such as immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to play a role, such as cancer, angiogensis, atheroscelerosis, graft rejection, rheumatoid arthritis and psoriasis.
    Type: Grant
    Filed: June 26, 2000
    Date of Patent: December 24, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Helen M. Armstrong, Richard Beresis, Joung L. Goulet, Mark A. Holmes, Xingfang Hong, Sander G. Mills, William H. Parsons, Peter J. Sinclair, Mark G. Steiner, Frederick Wong, Dennis M. Zaller